{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-011941","form_type":"8-K","ticker":"QCLS","cik":"0001321834","company_name":"Q/C TECHNOLOGIES, INC.","filed_at":"2023-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.378573+00:00","generated_at":"2026-06-17T02:57:30.109442+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MyMD doses 37 of 40 patients in Phase 2 trial of MYMD-1 for sarcopenia/frailty; no safety issues","bullets":["Safety Review Committee confirms no safety/toxicity issues with first 30 patients; unanimous vote to escalate to final dose level.","37 of 40 total patients randomized and dosed across four cohorts; only 3 patients away from dosing final patient.","Phase 2 double-blind, placebo-controlled study targets reduction of chronic inflammatory markers (IL-6, sTNFR-1) in patients aged 65+.","No FDA-approved treatments currently exist for sarcopenia/frailty; aging disorders market estimated at $600B by 2025.","Company planning early-stage trials for rheumatoid arthritis with MYMD-1."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-011941","json":"https://secwatch.observer/filing/0001493152-23-011941.json","markdown":"https://secwatch.observer/filing/0001493152-23-011941.md","text":"https://secwatch.observer/filing/0001493152-23-011941.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223011941/0001493152-23-011941-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223011941/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:57:30.109442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}